Skip to main content
. 2016 Nov 5;17(6):691–699. doi: 10.1007/s40257-016-0229-x
Psoriasis can affect a patient’s quality of life, which may be related to lesion location.
Adalimumab was associated with more prominent improvements in the head and trunk regions than in the extremities.
Significant clinical improvements in regional psoriasis severity correlated with meaningful improvements in quality of life.